In the latest episode of Inside Forbes India Podcast, Naini Thaker discusses her deep-dive profile on Dilip Shanghvi, the low-key founder of Sun Pharma, India's largest pharmaceutical company. Starting with just $200, Shanghvi's strategic focus on chronic therapies and high-value acquisitions—most notably Ranbaxy—helped shape Sun Pharma into a global force. The conversation explores how the company weathered challenges, such as price erosion, by doubling down on R&D and pivoting toward complex speciality drugs. It also highlights that Shanghvi's leadership is marked by humility, passion for his work, and a focus on patient care rather than wealth accumulation.